The present invention relates to an oral pharmaceutical composition comprising a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient, and a preparation method therefor.

The present invention relates to a novel indazole derivative, and a use thereof, wherein the indazole derivative has excellent TRIB2 or YAP inhibitory activity, and can be effectively used as a pharmaceutical composition for preventing or treating cancer, narcolepsy, and fasciitis.

A process for producing a solid pharmaceutical dosage formulation, said process comprising powder bed fusion selective laser 3-dimensional printing of a mixture comprising: (a)a drug; and (b)an excipient; whereinat least one of said drug and said excipient absorbs electromagnetic radiation at a wavelength emitted by the laser; or (a)a drug; (b)an excipient; and (c)an absorbent material which absorbs electromagnetic radiation at a wavelength emitted by the laser.

This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): ##STR00001##
or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

The present invention relates to a composition for recovering from and/or alleviating a hangover, containing Garcinia indica. The composition for recovering from and/or alleviating a hangover of the present invention has an excellent recovery and/or alleviation effect on a hangover, and thus the composition for recovering from and/or alleviating a hangover has high industrial usefulness.

Provided is a dissolution-enhanced olaparib composition, a preparation method therefor, a use thereof, and a medicament including the dissolution-enhanced olaparib composition. The dissolution-enhanced olaparib composition includes: olaparib; copovidone and a dissolution enhancer, wherein based on 100 parts by weight of olaparib, 100 or more and less than 200 parts by weight of copovidone, and 20 to 150 parts by weight of a dissolution enhancer. The dissolution-enhanced olaparib composition and the medicament prepared therefrom have controllable stability, increased oral absorption of the active ingredient, reduced excipient dosage, improved medication convenience, and are easy for industrial production.

The present invention is based on the highly soluble and bioavailable cannabinoid compositions which can be made at a commercial scale with a simple manufacturing process. Thus, the present invention relates to oral compositions comprising a cannabinoid compound, for use in the nutraceutical, pharmaceutical, food or beverage industries and its production methods.

An object of the present invention is to provide a tablet with excellent permeability and retention ability of active pharmaceutical ingredients. This object can be achieved with a tablet for being impregnated with an active pharmaceutical ingredient, with the tablet comprising a monosaccharide and/or disaccharide.

Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a tablet or liquid or a solid ODT or ODF or SMEDDS containing a ticagrelor or ticagrelor salt or combination with a second agent which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof, wherein the ODT or ODF or SMEDDS releases >50% of the ticagrelor or a pharmaceutically acceptable salt thereof and >50% of the second agent within 15 minutes.